Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients

The Efficacy and Safety of Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young Acute Myeloid Leukemia

The goal of this observational study is to to evaluate the efficacy and safety of Venetoclax in combination with DA60(daunorubicin 60 mg/m2/d for 3 days, and cytarabine 100 mg/m2 every 12 h for 7 days) induction and HD-AraC(cytarabine 3 g/m2 every 12 h for 3 days) consolidation, in young patients with newly diagnosed acute myeloid leukemia (AML).

Inclusion Criteria:

• Newly diagnosed, morphologically documented AML based on the World Health Organization (WHO) 2016 classification.
• Age ≥ 18 years and ≤ 59 years
• Have been treat with the "venetoclax in combination with standard induction and consolidation chemotherapy" therapy, and in follow-up.
• Be comprehensive of the research, and able to provide informed consent.

Exclusion Criteria:

• Diagnosis of acute promyelocytic leukemia (APL).
• Prior treatment for AML, except for: leukapheresis, hydroxyurea, and growth factor/cytokine.
• Unable to understand or participate.